TSHRThyroid Stimulating Hormone Receptor DIO2type 2 iodothyronine deiodinase SNP Information providing method for drug treatment decisions of hypothyroidism patients by TSHR mutations and DIO2 T92A single nucleotide polymorphism detection

摘要

The present invention relates to hypothyroidism treatment, and more specifically, to a microarray and kit for diagnosing a patient with hypothyroidism that needs, other than mono-therapy of administering L-T4 (levothyroxine) alone, co-administration of L-T3 (liothyronine), and a diagnosis method using the same. In the present invention, it was confirmed that the expression and activity of DIO2 protein due to thyroid stimulating hormone (TSH) are significantly inhibited when C.274AG (A on the DIO2 gene encoding the 274th base of the mRNA sequence encoding the DIO2 protein changes to G) homozygote SNP is present in type 2 iodothyronine deiodinase (DIO2) gene, and C.1349GA (A on the TSHR gene encoding the 1349th base of the mRNA sequence encoding the TSHR protein changes to G) heterozygote loss-of-function mutation is present in thyroid stimulating hormone receptor (TSHR) gene. Thus, the SNP of the DIO2 gene and TSHR mutation may be beneficially used in the diagnosis of a patient with hypothyroidism that needs the co-administration of L-T3.